Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wuling mycelia is a traditional Chinese medicine derived from the submerged fermentation of mycelial extracts of the fungus *Xylaria nigripes* (also known as wulingshen). [3, 4] It is investigated as a potential adjunct therapy for refractory epilepsy. [3] Preclinical studies in rats suggest its mechanism of action involves the downregulation of inflammatory factors such as nuclear factor kappa-B p65 subunit (NF-ĸB/p65), Toll-like receptor 4 (TLR4), and Interleukin-1 beta (IL-1β), thereby affecting the HMGB1/TLR4/NF-κB signaling pathway. [3] When used in combination with valproic acid in a rat model, Wuling mycelia was shown to reduce seizure frequency and protect against cognitive impairment. [3] It is also traditionally used for insomnia and to support neurological health. [4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on wuling mycelia.